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Abstract The aim of this study was
to assess nodal enhancement with ul-
trasmall superparamagnetic iron ox-
ide (USPIO)-enhanced magnetic res-
onance imaging (MRI) during preop-
erative staging of gynecological pel-
vic tumors within the same imaging
session for the primary tumor. Pelvic
MRI was performed 18–28 h after
intravenous infusion of USPIO
(Combidex/Sinerem, 2.6 mg Fe/kg
body weight) in 13 women (mean
age 51 years) scheduled for surgery
for biopsy proven (n=11) or clinical-
ly suspected (n=2) uterine carcino-
ma. Axial T1-weighted spin-echo
(SE), T2-weighted fast SE (FSE;
with fat saturation), fast spoiled gra-
dient-recalled (FSPGR) echo, sagit-
tal and oblique T2-weighted FSE se-
quences were acquired on a 1.5-T
system. Lymph nodes were prospec-
tively staged using standard criteria,
i.e., size and shape, as well as US-
PIO enhancement. Results were cor-
related with histology findings. MRI
correctly staged all primary uterine
tumors. In one case, the preoperative
diagnosis of stage IV switched the
therapeutic approach to ra-
diochemotherapy. Ninety-one (86
benign, 5 malignant) of the histolog-
ically characterized nodes could be
correlated with their MRI counter-
parts. One node was false positive;
three micrometastases greater than
5 mm and one 5-mm metastasis were
missed. On a nodal basis, the sensi-
tivity score was 0.33 and the speci-
ficity score, 0.99. On a patient basis,
the sensitivity score was 0.25 and the
specificity score, 0.80. Our prelimi-
nary results indicate that USPIO-en-
hanced pelvic MRI for preoperative
nodal assessment is feasible within
one imaging session for primary tu-
mors and that it has a high specifici-
ty. However, the low sensitivity in
the present study is a limitation for
the clinical application of this tech-
nique.
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Introduction
Primary tumor staging and nodal status are critical to
treatment planning and prognosis in uterine tumors, e.g.,
in cervical carcinoma where primary radiotherapy alone
is the treatment of choice for positive lymph nodes [1].
In addition to histologic grade and other factors, e.g.,
myometrial invasion in endometrial carcinoma or lesion
volume in cervical carcinoma, lymph node metastases
are a significant prognostic factor [2–5]. Staging follows
the International Federation of Gynecology and Obstet-
rics (FIGO) classification [6] and the TNM system [7].
Magnetic resonance imaging (MRI) is a reliable
method for staging gynecological pelvic tumors [8, 9].
However, like computed tomography (CT), it is less suit-
ed for assessing pelvic lymph node status. The major
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malignancy marker is a short-axis diameter of less than
1 cm [10, 11]. However, false-negative results for nor-
mal-sized malignant nodes and the impossibility of dif-
ferentiating between similarly hyperplastic metastatic vs
non-metastatic nodes impair staging performance [12].
Gadolinium (Gd) enhancement does not help in this re-
gard [13]. The continuing absence of a reliable imaging
method leaves surgical lymphadenectomy as the effec-
tive but invasive gold standard for lymph node staging in
uterine carcinoma.
The use of dextran-coated ultrasmall superparamag-
netic iron oxide (USPIO) particles may enhance the per-
formance of preoperative MRI in noninvasive staging.
USPIO is a lymph node-specific contrast agent under
clinical development as a contrast agent for intravenous
MR lymphography [14–16] among other indications. Af-
ter intravenous injection it extravasates into the interstiti-
al space before being transported to the lymph nodes
where in healthy nodes, it is taken up by macrophages,
resulting in signal loss—in contrast to a persistent signal
received from metastatic nodes [17]. Several clinical
studies in head and neck, mediastinal, and breast cancer
have confirmed that USPIO-enhanced MRI improves the
detection of lymph node metastases [16, 18–22].
Other groups have assessed USPIO for pelvic lymph
node detection in urologic and pelvic cancers, but they
included only one or two cases of uterine tumor [12, 23].
Our purpose was to perform a dedicated prospective
study in patients with gynecological pelvic tumors
specifically to explore the feasibility and utility of 
USPIO in preoperative primary tumor staging and lymph
node mapping.
Materials and methods
Thirteen women [age 51±14 years (mean ± 1 standard deviation),
range 32–73; height 163±6 cm, range 151–171; weight 66±14 kg,
range 48–90] with biopsy proven carcinoma of the cervix (n=7),
uterine corpus (n=3), or vulva (n=1), or uterine tumor suspected
on clinical and ultrasound or CT grounds (n=2), were included in
a prospective phase IIIb study. All were scheduled for surgery at
the time of inclusion. Noninclusion criteria were pregnancy or lac-
tation, standard contraindications to MRI, known allergy to dex-
trans or drugs containing iron salts, or a strong allergic disposi-
tion. Our institutional review board approved the protocol, and we
obtained written informed consent from all patients prior to study
entry.
The contrast agent [ferumoxtran (USAN); AMI-227; Com-
bidex/Sinerem, Advanced Magnetics, Inc., Boston, USA and
Guerbet, Roissy, France] was administered intravenously
through a filter as a slow drip infusion (2.6 mg Fe/kg body
weight diluted in 100 ml 0.9% saline solution) using a flow rate
of 2–4 ml/min [22]. The average total infusion time was 45 min.
The pelvic region was imaged on a 1.5-T MR system (Signa CV
or Horizon, GEMS, Milwaukee, Wis.) 18–28 h later using a pel-
vic or torso phased-array coil. The following 2D sequences were
acquired after a localizer: (a) axial T1-weighted spin-echo [SE;
TR 350–500 ms, TE 8 ms, matrix 256×256, field of view (FOV)
24–28 cm, slice thickness/gap 5–6/1 mm]; (b) axial (with fat sat-
uration) and sagittal (without fat saturation) T2-weighted fast SE
[FSE; TR 3,000–6,000 ms, TE 100 ms, matrix 512×512, FOV
24–28 cm, slice thickness/gap 5–6/1 mm (axial) or 4–5/1 mm
(sagittal)]; and (c) axial fast spoiled gradient-recalled (FSPGR)
echo sequences [TR 80 ms, TE 8 ms (first seven patients), or TR
255 ms, TE 4 ms (last six patients, to minimize problems with
chemical shift artifacts), flip angle 40°, matrix 256×256, FOV
24–28 cm, slice thickness/gap 5–6/1 mm]. All axial planes were
acquired from the aortic bifurcation to the ischial tuberosity us-
ing an identical table position, slice thickness and intersection
gap. Subsequently, for primary tumor staging in all cases of cer-
vical carcinoma, we performed an axial-oblique (perpendicular
to the cervical canal) T2-weighted FSE sequence (TR
3,300–5,500 ms, TE 100 ms, matrix 512×512, FOV 20–24 cm,
slice thickness/gap 3.5–4/0.5–1 mm). In all cases of uterine cor-
pus tumor, additional Gd-enhanced sagittal T1-weighted SE se-
quences (TR 460 or 540 ms, TE 8 or 20 ms, matrix 256×256,
FOV 20–24 cm, slice thickness/gap 5/1 mm; Gd-DTPA, 
Magnevist, Schering AG, Berlin, Germany, 0.1 mmol/kg body
weight) were acquired.
All image data were transferred to a Sun microsystems console
(Advantage Workstation 3.1, GEMS, Milwaukee, Wis.) for
prospective nodal analysis. In each case, all lymph nodes from the
aortic bifurcation to the iliac region were assessed, including the
inguinal nodes in the case of vulvar carcinoma, given the usual
pattern of metastatic spread in such tumors. To identify small
nodes and improve differentiation between lymph nodes and the
many vessels in this region, we synchronized the axial T1-weight-
ed SE, T2-weighted FSE and FSGPR, and sagittal T2-weighted
sequences, and cross-referenced the images. We characterized
lymph nodes by size and USPIO enhancement. We measured size
on T1-weighted SE images to minimize interference with suscepti-
bility effects (metastasis=short axis diameter >10 mm [10, 11]).
We analyzed nodal USPIO uptake primarily on the gradient-echo
sequence. In our clinical study setting, the intention was to per-
form primary tumor and lymph node staging in one imaging ses-
sion, no pre-USPIO images were available. Thus in contrast to
most previous studies, USPIO uptake could not be characterized
by comparing native and USPIO-enhanced images. We considered
lymph nodes showing homogeneous USPIO uptake or rim en-
hancement on gradient-echo sequences as benign, and those show-
ing heterogeneous or absent USPIO uptake as malignant [22].
Thus each lymph node was classified as benign or malignant by
USPIO enhancement, numbered and documented on film. Mor-
phological criteria were recorded; however, decision making was
based finally on USPIO enhancement. A consensus diagnosis was
reached by a board-certified radiologist and a resident experienced
in MRI, both blinded to the clinical findings. Primary tumors were
staged separately by a board-certified radiologist experienced in
genitourinary imaging from hard-copy films using standard crite-
ria [24–27].
The MR T and N staging results, including the detailed map-
ping of suspected malignant lymph nodes, were reported preopera-
tively to the referring physician. Surgery was performed in all but
one case, a patient with an undifferentiated sarcoma of the cervix
whose preoperative imaging showed advanced spread. A biopsy
only was done and the patient was then referred for ra-
diochemotherapy (Fig. 4). No lymphadenectomy was performed
in two other cases: a suspected uterine sarcoma in which an ovari-
an tumor was found intraoperatively (Fig. 5), and a case of cervi-
cal carcinoma treated with vaginal hysterectomy only, given the
early stage (pT1a) of the primary tumor. In a fourth case, a sus-
pected uterine tumor, hemicolectomy was performed after intraop-
erative discovery of cecal carcinoma invading the uterus and small
intestine. These four patients were excluded from our lymph node
analysis. Vulvectomy including inguinal lymphadenectomy was
performed in the case of vulvar carcinoma. All other patients un-
derwent hysterectomy and pelvic lymphadenectomy, extended in
some cases to adnexectomy or appendectomy.
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The final tumor diagnosis and the nodal staging histology find-
ings were then correlated with the MRI findings. To permit node-
to-node correlation, the smaller number of nodes detected—
whether by MRI or histology—was defined as the total number in
the patient concerned. The sensitivity, specificity and accuracy of
lymph node analysis were calculated per node and per patient us-
ing Excel 1997 (Microsoft, Redmond, Wash.).
Results
MRI of the primary tumor and USPIO-enhanced imaging
of the lymph nodes proved feasible in all patients. The
average total examination time of 45 min was well toler-
ated in all cases. There were no serious reactions to US-
PIO. Five patients (39%) displayed mild reactions: a
short episode of flush and dyspnea shortly after the start
of the infusion (n=2), regressing after pausing the infu-
sion which was then completed in both cases at a re-
duced flow rate (1–2 ml/min); erythema and pruritus
over the injection area (n=2), resolving 10–15 min after
the administration of an antihistamine combined with a
steroid; and self-resolving mild itchiness and erythema
on one leg (n=1). Reactions were moderate in two cases
(15%): urticaria and pruritus on the trunk, neck and arms
shortly after completing the infusion in one patient with
a history of hay fever and erythema, resolving 1 h after
oral and intravenous antihistamines and steroids; dys-
pnea, chest pain, pruritus and erythema in another pa-
tient shortly before completing the infusion, with sponta-
neous resolution 1 h later (the patient refused systemic
treatment).
The final histologic diagnosis (Table 1) included cer-
vical tumors (cervical carcinoma n=6, undifferentiated
sarcoma n=1) in seven patients [stage pT1a (n=2), pT1b
(n=4); the undifferentiated sarcoma was staged T4 on
clinical and imaging grounds]; endometrial carcinoma
(n=3: stages pT1b, pT1c and pT2b); and vulvar carcino-
ma (n=1: stage pT2) (Figs. 1, 2, 3, 4). Preoperative MRI
correctly T-staged all these tumors. It also correctly sug-
gested an ovarian lesion in a patient with clinical and
sonographic evidence favoring uterine sarcoma (Fig. 5).
Histology showed a clear-cell ovarian cystadenofibroma
of borderline malignancy and endometrial hyperplasia
within an endometrial polyp. In another patient with
uterine carcinoma indicated by the gynecologic examina-
tion and CT findings, histology showed a cecal carcino-
ma (pT4) invading the uterus and small intestine. We ex-
cluded four cases from further lymph node analysis: the
stage pT4 undifferentiated sarcoma of the cervix; the
early cervical carcinoma which did not undergo pelvic
lymphadenectomy; the clear-cell borderline ovarian cys-
tadenofibroma; and the invasive cecal carcinoma (Ta-
ble 1).
The smallest lymph nodes that could be confidently
differentiated from other anatomic structures measured
about 2 mm. Differentiation was problematic below this
limit. MRI identified 173 lymph nodes in the 13 patients,
classifying 30 as malignant by USPIO enhancement crite-
ria (Table 1). In the nine patients retained in the final sta-
tistical analysis, MRI identified a total of 107 lymph
nodes, six of which were deemed malignant (range
5–15 mm) and 101 as benign (range 2–10 mm). Histology
identified a total of 186 lymph nodes, six of which were
metastatic; 91 of the histologically characterized nodes
could be correlated with their MRI counterparts using our
study criteria; 86 were correctly staged by MRI (95% ac-
curacy), two of which were malignant (small diameter
>10 mm). One node was false-positive, while three mi-
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Fig. 1a–d A 65-year-old patient (no. 9, Table 1) with endometrial
carcinoma (pT1b N0). a Sagittal Gd-enhanced T1-weighted SE
(TR 540 ms, TE 20 ms), primary tumor (arrows); b axial T1-
weighted SE (TR 460 ms, TE 8 ms), homogeneous USPIO uptake
in all lymph nodes; c axial FSPGR (TR 255 ms, TE 4.2 ms, flip
angle 40°), same; d histologic confirmation of nonmetastatic
nodes. (H&E, ×10)
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crometastases (<5 mm) and one metastasis (5 mm) were
missed (Fig. 1). On a nodal basis, the sensitivity score was
therefore 0.33 and the specificity score, 0.99.
As for lymph node status on a patient basis, MRI cor-
rectly staged four node-negative patients (cervical carci-
noma, n=2; endometrial carcinoma, n=2); it misdiag-
nosed, as node-negative, two patients with micrometas-
tases (cervical carcinoma. n=1; endometrial carcinoma,
n=1), and one with a malignant lymph node (5 mm cer-
vical carcinoma metastasis); it correctly staged the vul-
var carcinoma as node-positive (Fig. 2), and made a
false-positive identification in one cervical carcinoma
patient. On a patient basis, the sensitivity score was
therefore 0.25 and the specificity score, 0.80.
In the patient with a final diagnosis of cecal carcino-
ma, MRI correctly found multiple lymph node metastas-
Fig. 2a–d A 72-year-old pa-
tient (no. 11, Table 1) with 
vulvar carcinoma (pT2 N1). 
a Axial T1-weighted SE 
image (TR 440 ms, TE 8 ms),
primary tumor (arrow); b axial
T1-weighted SE (TR 440 ms,
TE 8 ms), multiple enlarged
right inguinal nodes (arrows); 
c axial FSPGR (TR 255 ms, 
TE 4.2 ms, flip angle 40°), high
signal indicating no USPIO up-
take (arrows); d histologic con-
firmation of metastatic nodes
(cross-section of the vulvar car-
cinoma. Inset: lymph node me-
tastasis; H&E, ×40)
Table 1 Population MRI and histology data (ca carcinoma, LN lymph nodes)
Patient no. Final diagnosis Stage LN: MRIa LN: Histologya LN staging: MRI
1 Cervical ca. pT1b1 N0 0/2 0/32 Correct
2 Cervical ca. pT1b1 N1 0/23 2/14 Micrometastases missed (n=2)
3 Cervical ca. pT1a N0 0/18 0/18 Correct
4 Cervical ca. pT1b1 N0 1/7 0/41 False-positive hyperplastic node (n=1)
5 Cervical ca. pT1b1 N1 0/10 1/10 5 mm metastasis missed (n=1)
6 Undifferentiated T4 18/37 (No histologic (Excluded from analysis)
sarcoma of cervix staging)
7 Cecal ca. pT4 N2 6/17 16/20 (Excluded from analysis)
8 Cervical ca. pT1a Nx 0/6 (No lymph- (Excluded from analysis)
adenectomy)
9 Endometrial ca. pT1b N0 0/9 0/26 Correct
10 Endometrial ca. pT2b N0 0/2 0/12 Correct
11 Vulvar ca. pT2 N1 5/18 2/11 Correct
12 Clear-cell ovarian pT1a 0/6 (No lymph- (Excluded from analysis)
cystadenofibroma, (borderline) adenectomy)
endometrial polyp 
with hyperplasia
13 Endometrial ca. pT1c N0 0/18 1/2 2 Micrometastasis missed (n=1)
a Malignant/total
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es (six out of a total of 17 nodes). However, locoregional
invasion complicated the task of differentiation from in-
testinal structures, particularly in the case of metastatic
mesenteric nodes, 16 of 20 of which proved malignant
on histology (this case had to be excluded from the sta-
tistical analysis due to the primary tumor histology, de-
spite the correlation available with the histology).
Discussion
The study shows the feasibility of a same-session imag-
ing strategy for uterine tumors incorporating primary tu-
mor assessment and lymph node mapping. In addition to
contrast injection the previous day, lymph node imaging
using USPIO-enhanced MRI requires only one addition-
al sequence of about 5 min (axial FSPGR) and is thus
feasible in a routine clinical setting. Nodal analysis on
the workstation, however, was relatively time-consuming
mainly because of the fine-detail mapping (≥2 mm) and
the confounding adjacent structures, notably blood ves-
sels.
We saw no serious reactions to USPIO. However, we
observed milder and transiently moderate reactions than
reported in the literature, despite comparable conditions
[22]. The explanation probably lies in coincidental accu-
mulation in our relatively small population.
We confirmed earlier reports that MRI is a reliable
technique for T-staging primary uterine tumors. Its only
failure was in the case of the cecal carcinoma, due to the
Fig. 3a–d A 38-year-old pa-
tient (no. 2, Table 1) with cer-
vical carcinoma (pT1b N1). 
a Sagittal T2-weighted FSE
image (TR 6,000 ms, TE
100 ms), primary tumor 
(arrowhead) and nabothian cyst
(arrows); b axial T1-weighted
SE (TR 460 ms, TE 8 ms),
small lymph nodes (arrows)
with homogeneous USPIO up-
take; c axial FSPGR sequences
(TR 80 ms, TE 8 ms, flip angle
40°), same; d histologic contra-
diction of MRI findings 
[micrometastasis (arrow) of
one lymph node; H&E, ×75]
extensive invasion of adjacent organs. In the suspected
uterine sarcoma case, eventually diagnosed as a combi-
nation of clear-cell borderline ovarian cystadenofibroma
and endometrial hyperplasia, MRI aided the preoperative
strategy by identifying an ovarian lesion.
Small nodal metastases are difficult to diagnose on
cross-sectional imaging. Metastatic nodes can vary in di-
ameter: not only can the larger nodes not be differentiat-
ed from normally reactive nodes of equal size, but signal
intensities from metastatic nodes do not differ from those
of normal nodes [28]. The specificity of USPIO-en-
hanced MRI is that it differentiates between enlarged re-
active and metastatic nodes [29] and also detects normal-
sized metastatic nodes [12]. However, our nodal analysis
yielded different sensitivity results than those published
in the literature [12, 16, 30]. Although nodal involve-
ment was detected with satisfactory specificity in terms
of the literature data, on both a nodal and patient basis,
sensitivity was poor. One explanation might lie in our
relatively small sample size. Another is that most tumors
in our population were at the early stage when lymph
node mapping has its greatest impact on therapeutic
strategy. Many such patients are likely to be node-nega-
tive or have micrometastases. With only one true-posi-
tive case (vulvar carcinoma with inguinal metastases)
and three false-negative cases at histology, our results
must be considered preliminary and interpreted with the
appropriate caution. However, in two of the three false-
negative cases (cases 2 and 13 in Table 1), the histology
showed micrometastases only. Other groups have report-
ed false-negative micrometastatic nodes [30, 31]. Hard-
ware and software constraints prevent MRI from resolv-
ing these microstructures for the time being. Contrast
dose-dependent susceptibility artifacts in the gradient-
echo pulse (GRE) sequences are another reason for mis-
sing microlesions [30]. The high sensitivity of GRE im-
aging to magnetic susceptibility effects can cause over-
estimation of nodal size [32] and signal homogenization
of nodal content [30]. Improved micrometastasis detec-
tion rates may therefore have to await the optimization
not only of spatial resolution but also of the USPIO-sen-
sitive GRE sequences and contrast dose.
Furthermore, we encountered some problems in nodal
analysis that we believe to be pelvis-specific. In contrast
to axillary lymph nodes, which are surrounded by fatty
tissue and thus readily differentiated from adjacent struc-
tures [22], pelvic nodes are typically small and often dif-
ficult to distinguish from vessels, the intestinal chemical
shift, and USPIO artifacts on GRE sequences. Further-
more, in contrast to the axilla or neck, the region to be
imaged (i.e., right and left iliac) is relatively large, re-
sulting in a trade-off between spatial resolution and com-
prehensiveness when selecting imaging parameters, i.e.,
field-of-view and slice thickness. Image quality was ad-
ditionally hampered in some of our cases by gut motion
artifacts, a problem which might have been overcome by
the use of spasmolytics. Neither operator nor hardware
factors are likely to be sufficient explanations for poor
sensitivity in that an axillary lymph node study per-
formed under identical conditions achieved markedly su-
perior sensitivity [22].
A further limitation of this preliminary study was our
small population of 13 patients, four of whom were ex-
cluded from the final statistical analysis. This was sim-
ply due to the fact that our referring gynecology depart-
942
Fig. 4a–d A 36-year-old patient (no. 6, Table 1) with large uterine
mass. a Sagittal T2-weighted FSE image (TR 4,700, TE 100 ms),
leiomyoma (arrowheads) and large heterogeneous tumor of the
cervix (arrows); b axial T1-weighted SE (TR 340, TE 8 ms), mul-
tiple enlarged iliac lymph nodes with no USPIO uptake, best seen
on GRE sequences; c axial FSPGR (TR 80 ms, TE 8 ms, flip angle
40°), same; d biopsy specimen of the cervical tumor with histolog-
ic diagnosis of an undifferentiated sarcoma of the cervix (H&E,
×100)
Fig. 5a–d A 56-year-old pa-
tient (no. 12, Table 1) with
clinically suspected uterine sar-
coma. Histology showed an
ovarian lesion as well as endo-
metrial hyperplasia. a Axial
T2-weighted FSE (TR 3,500,
TE 100 ms), ovarian lesion
(arrows) next to uterus (arrow-
head); b axial FSPGR (TR 250,
TE 8 ms, flip angle 40°), sever-
al normal-size lymph nodes
with complete USPIO uptake
(arrows); c resected ovarian tu-
mor 16×10×9 cm: polylobulat-
ed mass of 673 g with a cen-
trally located cyst filled with
blood (macroscopic specimen);
d borderline clear-cell cystade-
nofibroma (H&E, ×30. Inset:
glandular structures with atypi-
cal nuclei and some mitoses
without invasion, ×125. Endo-
metrial hyperplasia and polyp
not shown)
operative nodal mapping in selected cases. However, fur-
ther studies in a larger population using improved spatial
resolution are needed to evaluate this novel imaging
strategy in a clinical setting.
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ment sees 20 times fewer cases of operable uterine tumor
than, for example, breast cancer. We had to halt recruit-
ment to our uterine tumor study after exceeding the time
limit agreed with the contrast agent company.
In conclusion, USPIO-enhanced MRI of the pelvic
nodes is a feasible addition to plain or Gd-enhanced pel-
vic MRI in patients with uterine tumors. Our preliminary
results suggest that it can be a valuable adjunct for pre-
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